Jason P. Rhodes - 04 Oct 2021 Form 4 Insider Report for Gemini Therapeutics, Inc. /DE (IRON)

Role: Director, 10%+ Owner
Signature: /s/ Jason Meyenburg, attorney-in-fact
Issuer symbol: IRON
Transactions as of: 04 Oct 2021
Transactions value $: $0
Form type: 4
Filing time: 06 Oct 2021, 16:15:39 UTC
Previous filing: 29 Sep 2021
Next filing: 05 Apr 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IRON	Stock Option (Right to Buy)	Award	$0	+17.2K		$0.00	17.2K	04 Oct 2021	Common Stock	17.2K	$3.80	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.
F2	This option was granted to the Reporting Person, a director of the Issuer and a member of Atlas Venture Life Science Advisors, LLC ("Atlas"). The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Content

This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

This option was granted to the Reporting Person, a director of the Issuer and a member of Atlas Venture Life Science Advisors, LLC ("Atlas"). The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.